Literature DB >> 12589478

Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine.

Dirk Pauleit1, Frank Floeth, Hans Herzog, Kurt Hamacher, Lutz Tellmann, Hans-W Müller, Heinz H Coenen, Karl-J Langen.   

Abstract

The whole-body distribution of O-(2-[(18)F]fluoroethyl)- l-tyrosine (FET) was studied in seven patients with brain tumours by positron emission tomography (PET). Based on the IMEDOSE and MIRDOSE procedures, radiation absorbed doses were estimated from whole-body PET scans acquired approximately 70 and 200 min after i.v. injection of 400 MBq FET. After injection of FET, the peak of radioactivity in the blood was observed after 1.5 min, and a plateau of nearly constant radioactivity was reached at 20 min. The whole-body distribution of FET showed the highest activities in the urinary tract. All other organs exhibited only moderate FET uptake (SUV </=1.6) which remained constant between early and late PET scans. No increased uptake was seen in the bone, the biliary tract or the pancreas. Twenty-two percent of the injected activity was excreted 5 h p.i. (approx. 5.3% ID/h). The highest absorbed dose was found for the urinary bladder wall. The effective dose according to ICRP 60 was 16.5 micro Sv/MBq for adults, which would lead to an effective dose of 6.1 mSv in a PET study using 370 MBq FET.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12589478     DOI: 10.1007/s00259-003-1118-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  18 in total

Review 1.  Recent advances of PET in the diagnosis of brain tumors.

Authors:  K J Langen; M Weckesser
Journal:  Front Radiat Ther Oncol       Date:  1999

2.  Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo.

Authors:  P Heiss; S Mayer; M Herz; H J Wester; M Schwaiger; R Senekowitsch-Schmidtke
Journal:  J Nucl Med       Date:  1999-08       Impact factor: 10.057

3.  Calculation of residence times and radiation doses using the standard PC software Excel.

Authors:  H Herzog; H Zilken; A Niederbremer; W Friedrich; H W Müller-Gärtner
Journal:  Eur J Nucl Med       Date:  1997-12

4.  Whole-body kinetics and dosimetry of L-3--123I-iodo-alpha-methyltyrosine.

Authors:  D Schmidt; K J Langen; H Herzog; J Wirths; M Holschbach; J C Kiwit; K Ziemons; H H Coenen; H Müller-Gärtner
Journal:  Eur J Nucl Med       Date:  1997-09

5.  O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study.

Authors:  W A Weber; H J Wester; A L Grosu; M Herz; B Dzewas; H J Feldmann; M Molls; G Stöcklin; M Schwaiger
Journal:  Eur J Nucl Med       Date:  2000-05

Review 6.  [The role of L-3-I-123-iodine-alpha-methyltyrosine SPECT in cerebral gliomas].

Authors:  M Weckesser; D Schmidt; P Matheja; H H Coenen; K J Langen
Journal:  Nuklearmedizin       Date:  2000-12       Impact factor: 1.379

Review 7.  Radiolabeled amino acids: basic aspects and clinical applications in oncology.

Authors:  P L Jager; W Vaalburg; J Pruim; E G de Vries; K J Langen; D A Piers
Journal:  J Nucl Med       Date:  2001-03       Impact factor: 10.057

8.  (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection.

Authors:  Achim H Kaim; Bruno Weber; Michael O Kurrer; Gerrit Westera; Alain Schweitzer; Jochen Gottschalk; Gustav K von Schulthess; Alfred Buck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-06       Impact factor: 9.236

Review 9.  Fluorinated amino acids for tumour imaging with positron emission tomography.

Authors:  Peter Laverman; Otto C Boerman; Frans H M Corstens; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-01-11       Impact factor: 9.236

10.  Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging.

Authors:  H M Deloar; T Fujiwara; M Shidahara; T Nakamura; H Watabe; Y Narita; M Itoh; M Miyake; S Watanuki
Journal:  Eur J Nucl Med       Date:  1998-06
View more
  26 in total

1.  EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues.

Authors:  T Vander Borght; S Asenbaum; P Bartenstein; C Halldin; O Kapucu; K Van Laere; A Varrone; K Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

2.  Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-L-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake.

Authors:  Carina Stegmayr; Gabriele Stoffels; Elena Rota Kops; Philipp Lohmann; Norbert Galldiks; Nadim J Shah; Bernd Neumaier; Karl-Josef Langen
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

3.  O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.

Authors:  M Weckesser; K J Langen; C H Rickert; S Kloska; R Straeter; K Hamacher; G Kurlemann; H Wassmann; H H Coenen; O Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-14       Impact factor: 9.236

4.  18F-Fluoroethyl-tyrosine uptake is correlated with amino acid transport and neovascularization in treatment-naive glioblastomas.

Authors:  Friederike Liesche; Mathias Lukas; Christine Preibisch; Kuangyu Shi; Jürgen Schlegel; Bernhard Meyer; Markus Schwaiger; Claus Zimmer; Stefan Förster; Jens Gempt; Thomas Pyka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-09       Impact factor: 9.236

5.  Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients.

Authors:  Hansjörg Vees; Srinivasan Senthamizhchelvan; Raymond Miralbell; Damien C Weber; Osman Ratib; Habib Zaidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-26       Impact factor: 9.236

6.  Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.

Authors:  Gabriele Pöpperl; Claudia Götz; Walter Rachinger; Franz-Josef Gildehaus; Jörg-Christian Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-10       Impact factor: 9.236

7.  Radiosynthesis and biological evaluation of alpha-[F-18]fluoromethyl phenylalanine for brain tumor imaging.

Authors:  Chaofeng Huang; Liya Yuan; Keith M Rich; Jonathan McConathy
Journal:  Nucl Med Biol       Date:  2013-03-23       Impact factor: 2.408

8.  Biodistribution and radiation dosimetry in healthy volunteers of a novel tumour-specific probe for PET/CT imaging: BAY 85-8050.

Authors:  Kamilla Smolarz; Bernd Joachim Krause; Frank Philipp Graner; Franziska Martina Wagner; Hans-Jürgen Wester; Tina Sell; Claudia Bacher-Stier; Lüder Fels; Ludger Dinkelborg; Markus Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-23       Impact factor: 9.236

9.  Diagnostics of cerebral gliomas with radiolabeled amino acids.

Authors:  Karl-Josef Langen; Klaus Tatsch; Anca-Ligia Grosu; Andreas H Jacobs; Matthias Weckesser; Osama Sabri
Journal:  Dtsch Arztebl Int       Date:  2008-01-25       Impact factor: 5.594

10.  Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data.

Authors:  Tuula Tolvanen; Timo Yli-Kerttula; Tiina Ujula; Anu Autio; Pertti Lehikoinen; Heikki Minn; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.